Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL858849 | 0.90 | LMNA (0.42) | LMNAKDM4EALDH1A1GLAGLS | |
| SCHEMBL10277607 | 0.77 | ALDH1A1 (0.57) | LMNAKDM4EALDH1A1GLAGLS | |
| SCHEMBL266824 | 0.72 | LMNA (0.70) | LMNAKDM4EALDH1A1CYP1A2GAA | |
| SCHEMBL16998703 | 0.70 | LMNA (0.50) | LMNAKDM4EALDH1A1RCE1GAA | |
| SCHEMBL16998615 | 0.70 | LMNA (0.46) | LMNAKDM4EALDH1A1GAAHPGD | |
| SCHEMBL859902 | 0.70 | — | — | |
| SCHEMBL94392 | 0.70 | — | — | |
| SCHEMBL17489160 | 0.69 | GLS (0.75) | LMNAKDM4EALDH1A1GLAGLS | |
| SCHEMBL16447617 | 0.69 | ALDH1A1 (0.64) | LMNAKDM4EALDH1A1GLAGLS | |
| Hydrochloric Acid SCHEMBL8660596 | 0.69 | ALDH1A1 (0.57) | LMNAKDM4EALDH1A1GLAGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | LMNA 2913/4885KDM4E 3841/4885ALDH1A1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.